Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from AIM ImmunoTech ( (AIMI) ).
On June 11, 2025, AIM ImmunoTech announced that it has regained compliance with the NYSE American’s listing requirements, and its common stock is expected to be reinstated for trading on June 17, 2025, under the ticker symbol ‘AIM’. This follows the company’s recent 1-for-100 reverse stock split, approved by stockholders on April 30, 2025, which aims to increase the per-share market price of its common stock. The reverse split is part of AIM ImmunoTech’s strategy to enhance its market position and comply with exchange regulations, potentially impacting stakeholders by stabilizing its stock’s market presence.
The most recent analyst rating on (AIMI) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIMI Stock Forecast page.
Spark’s Take on AIMI Stock
According to Spark, TipRanks’ AI Analyst, AIMI is a Neutral.
AIM ImmunoTech’s overall score is primarily affected by its financial performance, which shows significant challenges, including declining revenue and negative cash flow. Technical analysis and valuation further suggest caution, given bearish trends and a lack of profitability. The earnings call provided some positive strategic insights, but financial constraints and delisting risks remain major concerns.
To see Spark’s full report on AIMI stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The company’s lead product is Ampligen®, a first-in-class investigational drug with broad spectrum activity in clinical trials for globally important cancers, viral diseases, and immune system disorders.
Average Trading Volume: 397,596
Technical Sentiment Signal: Sell
Current Market Cap: $5.54M
For an in-depth examination of AIMI stock, go to TipRanks’ Overview page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue